A Phase 2 Trial of Belzupacap Sarotalocan (AU-011), a First-in-Class Targeted Therapy for Choroidal Melanoma via Suprachoroidal Administration

A Phase 2 Trial of Belzupacap Sarotalocan (AU-011), an Investigational, Virus-Like Drug Conjugate (VDC) for the Treatment of Primary Indeterminate Lesions and Small Choroidal Melanoma (IL/CM) using Suprachoroidal Administration – (NCT04417530)

New Developments in Belzupacap Sarotalocan (AU-011), an Investigational Virus-Like Drug Conjugate (VDC) in Ocular Oncology

Clinical Evaluation of Belzupacap Sarotalocan (AU-011), a First-in-Class Targeted Therapy for Choroidal Melanoma with Intravitreal or Suprachoroidal Route of Administration

Topline Data from a Retrospective, Matched Case Study Evaluating Belzupacap Sarotalocan (AU-011) versus Plaque Radiotherapy, Supports the Value of a Vision Preserving Therapy for the Treatment of Patients with Early-Stage Choroidal Melanoma

A Phase 2 Trial of belzupacap sarotalocan (AU-011), a First-in-class Targeted Therapy for Choroidal Melanoma via Suprachoroidal (SC) Administration

A Phase 1b/2 Trial of belzupacap sarotalocan (AU-011), a First-in-Class Targeted Therapy for the Treatment of Choroidal Melanoma via Intravitreal Administration

A First in Class Virus-Like Drug Conjugate (VDC) Shows Anti-tumor Activity in Cancers that Commonly Metastasize to the Choroid

Biological assessment of the virus-like drug conjugate AU-011 to specifically target a breadth of human cancer types

Targeting urothelial neoplasia using an investigational virus-like drug conjugate